Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 139

1.

Bortezomib-based regimens in patients with POEMS syndrome: a case series in newly diagnosed and relapsed patients.

Riva M, Lessi F, Berno T, Visentin A, Campagnolo M, Semenzato G, Adami F, Briani C.

Leuk Lymphoma. 2019 Jan 22:1-4. doi: 10.1080/10428194.2018.1564048. [Epub ahead of print] No abstract available.

PMID:
30668203
2.

Whole-body low-dose CT recognizes two distinct patterns of lytic lesions in multiple myeloma patients with different disease metabolism at PET/MRI.

Zambello R, Crimì F, Lico A, Barilà G, Branca A, Guolo A, Varin C, Vezzaro R, Checuz L, Scapin V, Berno T, Pizzi M, Ponzoni A, De Biasi E, Vio S, Semenzato G, Zucchetta P, Lacognata C.

Ann Hematol. 2019 Mar;98(3):679-689. doi: 10.1007/s00277-018-3555-7. Epub 2018 Dec 11.

PMID:
30539276
3.

Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience.

Filì C, Candoni A, Zannier ME, Olivieri J, Imbergamo S, Caizzi M, Nadali G, Di Bona E, Ermacora A, Gottardi M, Facchinelli D, Ciancia R, Lazzarotto D, Dubbini MV, Festini G, Gherlinzoni F, Michieli MG, Semenzato G, Fanin R.

Leuk Res. 2019 Jan;76:33-38. doi: 10.1016/j.leukres.2018.11.015. Epub 2018 Nov 28.

PMID:
30529681
4.

Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib.

Breccia M, Bartoletti D, Bonifacio M, Palumbo GA, Polverelli N, Abruzzese E, Bergamaschi M, Tieghi A, Tiribelli M, Iurlo A, Cavazzini F, Sgherza N, Binotto G, Isidori A, D'Adda M, Crugnola M, Bosi C, Heidel F, Molica M, Scaffidi L, Cattaneo D, Latagliata R, Auteri G, Lemoli RM, Fanin R, Russo D, Aversa F, Cuneo A, Semenzato G, Catani L, Cavo M, Vianelli N, Foà R, Palandri F.

Ann Hematol. 2018 Dec 4. doi: 10.1007/s00277-018-3569-1. [Epub ahead of print]

PMID:
30515542
5.

Cortactin expression in non-Hodgkin B-cell lymphomas: a new marker for the differential diagnosis between chronic lymphocytic leukemia and mantle cell lymphoma.

Pizzi M, Trentin L, Visentin A, Saraggi D, Martini V, Guzzardo V, Righi S, Frezzato F, Piazza F, Sabattini E, Semenzato G, Rugge M.

Hum Pathol. 2018 Nov 17. pii: S0046-8177(18)30446-5. doi: 10.1016/j.humpath.2018.10.038. [Epub ahead of print]

PMID:
30458196
6.

Relevance of antiphospholipid antibody profile in the clinical outcome of ITP: a single-centre study.

Frison L, Lombardi A, Caputo I, Semenzato G, Fabris F, Vianello F.

Hematology. 2019 Dec;24(1):134-138. doi: 10.1080/10245332.2018.1532649. Epub 2018 Oct 25.

PMID:
30355275
7.

Mitochondrial apoptosis is induced by Alkoxy phenyl-1-propanone derivatives through PP2A-mediated dephosphorylation of Bad and Foxo3A in CLL.

Pagano MA, Tibaldi E, Molino P, Frezzato F, Trimarco V, Facco M, Zagotto G, Ribaudo G, Leanza L, Peruzzo R, Szabò I, Visentin A, Frasson M, Semenzato G, Trentin L, Brunati AM.

Leukemia. 2018 Oct 23. doi: 10.1038/s41375-018-0288-5. [Epub ahead of print]

PMID:
30353029
8.

Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients.

Palandri F, Palumbo GA, Bonifacio M, Breccia M, Latagliata R, Martino B, Polverelli N, Abruzzese E, Tiribelli M, Nicolosi M, Bergamaschi M, Tieghi A, Iurlo A, Sgherza N, Cavazzini F, Isidori A, Binotto G, Ibatici A, Crugnola M, Heidel F, Bosi C, Bartoletti D, Auteri G, Catani L, Cuneo A, Aversa F, Semenzato G, Cavo M, Vianelli N, Benevolo G.

Leuk Res. 2018 Nov;74:86-88. doi: 10.1016/j.leukres.2018.10.001. Epub 2018 Oct 5. No abstract available.

PMID:
30321784
9.

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial.

Trotman J, Barrington SF, Belada D, Meignan M, MacEwan R, Owen C, Ptáčník V, Rosta A, Fingerle-Rowson GR, Zhu J, Nielsen T, Sahin D, Hiddemann W, Marcus RE, Davies A; PET investigators from the GALLIUM study.

Lancet Oncol. 2018 Nov;19(11):1530-1542. doi: 10.1016/S1470-2045(18)30618-1. Epub 2018 Oct 8.

PMID:
30309758
10.

Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy.

Bonifacio M, Scaffidi L, Binotto G, Miggiano MC, Danini M, Minotto C, Griguolo D, Marin L, Frison L, D'Amore F, Basso M, Sartori R, Tinelli M, Stulle M, Fortuna S, Bonalumi A, Bertoldero G, De Biasi E, Ruggeri M, Semenzato G, Fanin R, Pizzolo G, Krampera M, Tiribelli M.

Leuk Res. 2018 Nov;74:75-79. doi: 10.1016/j.leukres.2018.09.018. Epub 2018 Oct 2.

PMID:
30308414
11.

Abnormal regulation of BCR signalling by c-Cbl in chronic lymphocytic leukaemia.

Martini V, Frezzato F, Severin F, Raggi F, Trimarco V, Martinello L, Molfetta R, Visentin A, Facco M, Semenzato G, Paolini R, Trentin L.

Oncotarget. 2018 Aug 14;9(63):32219-32231. doi: 10.18632/oncotarget.25951. eCollection 2018 Aug 14.

12.

Dabigatran in ibrutinib-treated patients with atrial fibrillation and lymphoproliferative diseases: Experience of 4 cases.

Visentin A, Campello E, Scomazzon E, Spiezia L, Imbergamo S, Pravato S, Piazza F, Semenzato G, Simioni P, Trentin L.

Hematol Oncol. 2018 Dec;36(5):801-803. doi: 10.1002/hon.2545. Epub 2018 Sep 6. No abstract available.

PMID:
30110712
13.

Possible neuroleukemiosis in two patients with acute myeloid leukemia in complete bone marrow remission.

Kostic I, Ruiz M, Branca A, Nabergoj M, Piazza F, Semenzato G, Gurrieri C, Briani C.

J Neurol Sci. 2018 Sep 15;392:63-64. doi: 10.1016/j.jns.2018.06.029. Epub 2018 Jun 30. No abstract available.

PMID:
30049661
14.

BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome.

Visentin A, Imbergamo S, Scomazzon E, Pravato S, Frezzato F, Bonaldi L, Pizzi M, Vio S, Gregianin M, Burei M, Facco M, Semenzato G, Piazza F, Trentin L.

Br J Haematol. 2018 Jul 5. doi: 10.1111/bjh.15440. [Epub ahead of print] No abstract available.

PMID:
29974955
15.

Benign TdT-positive cells in pediatric and adult lymph nodes: a potential diagnostic pitfall.

Pizzi M, Brignola S, Righi S, Agostinelli C, Bertuzzi C, Pillon M, Semenzato G, Rugge M, Sabattini E.

Hum Pathol. 2018 Nov;81:131-137. doi: 10.1016/j.humpath.2018.06.027. Epub 2018 Jun 30.

PMID:
29969607
16.

Dominant cytotoxic NK cell subset within CLPD-NK patients identifies a more aggressive NK cell proliferation.

Barilà G, Teramo A, Calabretto G, Ercolin C, Boscaro E, Trimarco V, Carraro S, Leoncin M, Vicenzetto C, Cabrelle A, Facco M, Piazza F, Semenzato G, Zambello R.

Blood Cancer J. 2018 Jun 5;8(6):51. doi: 10.1038/s41408-018-0088-1. No abstract available.

17.

Old and Young Actors Playing Novel Roles in the Drama of Multiple Myeloma Bone Marrow Microenvironment Dependent Drug Resistance.

Manni S, Carrino M, Semenzato G, Piazza F.

Int J Mol Sci. 2018 May 18;19(5). pii: E1512. doi: 10.3390/ijms19051512. Review.

18.

Splenic marginal zone lymphoma with a de novo t(8;14)(q24;q32) and a prolymphocytoid evolution responsive to rituximab-bendamustine.

Scapinello G, Pizzi M, Vio S, Nabergoj M, Visentin A, Martines A, Bonaldi L, Trentin L, Semenzato G, Piazza F.

Ann Hematol. 2018 Oct;97(10):2001-2003. doi: 10.1007/s00277-018-3351-4. Epub 2018 May 4. No abstract available.

PMID:
29728736
19.

In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics.

Rigolin GM, Saccenti E, Guardalben E, Cavallari M, Formigaro L, Zagatti B, Visentin A, Mauro FR, Lista E, Bassi C, Lupini L, Quaglia FM, Urso A, Bardi MA, Bonaldi L, Volta E, Tammiso E, Ilari C, Cafforio L, Melandri A, Cavazzini F, Negrini M, Semenzato G, Trentin L, Foà R, Cuneo A.

Br J Haematol. 2018 Apr;181(2):229-233. doi: 10.1111/bjh.15174. Epub 2018 Apr 2.

PMID:
29611195
20.

Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients.

Tiribelli M, Bonifacio M, Binotto G, Iurlo A, Cibien F, Maino E, Guella A, Festini G, Minotto C, De Biasi E, De Marchi F, Scaffidi L, Frison L, Bucelli C, Medeot M, Calistri E, Sancetta R, Stulle M, Orofino N, Krampera M, Gherlinzoni F, Semenzato G, Pizzolo G, Ambrosetti A, Fanin R.

Oncotarget. 2018 Feb 12;9(18):14219-14227. doi: 10.18632/oncotarget.24478. eCollection 2018 Mar 6.

Supplemental Content

Loading ...
Support Center